After Being Acquired By Sanofi In 2008, Very Little Had

After being acquired by Sanofi in 2008, very little had changed at the Genzyme Allston Landing Facility until recently. The honeymoon period is over and over the next year Sanofi will be replacing all of the existing Genzyme systems with Sanofi corporate systems. These changes will impact all departments across the site and adapting the new systems will be a challenge. Thankfully, the systems are being rolled out incrementally over the year rather than all at once. As a result of this approach, the continued use of existing systems for new project work is being discouraged beyond a specific date. The site change management system, currently Trackwise, will be replaced by Sanofi’s own system, Phenix. As an engineer, I am required to†¦show more content†¦Through various discussions with my manager and other individuals, I have discovered that this deadline was self-imposed by the QA CC group and not mandated by the company. For myself, and my team to be successf ul in achieving our project goals for the year, I feel I need to devise a strategy to allow our CCRs to be processed until at least the end of March. I believe this is possible through implementation of a strategy that uses the Cohen-Bradford model of influence without authority. In the scope of this strategy, our group is at an advantage because we have not only developed good working relationships with the QA CC group, but also have built a reputation for meeting the dates we set within the CCR process. This is the exception onsite as other groups often miss or extend the CCR process dates they set. Due to the relationship we have built with the QA CC group, our group see them as allies as they do us, which makes the first step of the Cohen-Bradford model easy to achieve. The next step in the model requires that my group fully understand our goals and priorities. Again, with this step I believe we have correctly prepared ourselves for success. The project list we developed in January includes a timeline for each project, with a projected start date, duration, and end date. This list allows us to narrow focus of the negotiation on two projects that were slated to initiate during the blackout period ofShow MoreRelatedSanofi Genzyme Merger4992 Words   |  20 Pagesthe possible deal after the company’s shareholder meeting in June. 6/28/2010- Viehbacher calls Termeer to set up a meeting and Termeer promises to respond soon. 7/2/2010- The media becomes alerted about Sanofi wishing to purchase a U.S. biotech company as rumors circulate about Genzyme. 7/29/2010- Sanofi sends a private letter to Genzyme’s board of directors offering $69/share in cash. 8/22/2010- Genzyme rejects Sanofi’s offer. 8/29/2010- Sanofi goes public withRead MoreThe Impacts of Mncs in the Economy of Bangladesh14643 Words   |  59 PagesMultinational Company is company which is originated in a country (home) and expands its activities through the world. The Indian Sub-continent has been an exquisite land of attraction for the businessmen since a long been.Bangladesh, after achieving birth in 1971 had become a fascinating body by the MNCs. As capitalization is going on through the world the MNCs are given an unwritten license to expand their business over the world. In this sequel action American Life Insurance Company ltd. LaunchedRead MoreProblems Facing the Pharmaceutical Industry and Approaches to Ensure Long Term Viability14741 Words   |  59 Pagesexecution of these strategies will have long term success. The issues involved are very complex and cover a wide variety of areas including research and development, commercial, political and geographical to name a few. This paper explores the commercial or business issues and their impact on the current Pharma business model. It will also look at strategies being devised to address the lack of innovative new products being developed and approved and the negative impact they have on revenue growth. ItRead MoreGlobal Pharmaceutical Industry Analysis7049 Words   |  29 Pagesare provided in the table below. Rank 2008 Company Country Total Revenues(USD millions) Healthcare RD 2006(USD millions) Net income/ (loss) 2006(USD millions) Employees 2006 1 Novartis Switzerland 53,324 7,125 11,053 138,000 2 Pfizer USA 48,371 7,599 19,337 122,200 3 Bayer Germany 44,200 1,791 6,450 106,200 4 GlaxoSmithKline United Kingdom 42,813 6,373 10,135 106,000 5 Johnson and Johnson USA 37,020 5,349 7,202 102,695 6 Sanofi-Aventis France 35,645 5,565 5,033 100Read MoreCosmetic Industry Analysis28098 Words   |  113 PagesIntroduction Global economy had experienced the worst recession in decades during 2008 till 2009 (Nouriel, 2009). Fear and panic were surrounded among people. During those days, the main headline of newspaper is about share market decreasing, industrial growth decreasing, and overall instability of the economy. Rumors are thick and flying, as a result, it create more fear among people and households about their savings and hard earned income. Most countries are affected by the recession, especiallyRead MoreMergers Acquisitions in Pharma Industry21425 Words   |  86 Pagesbase. By this Research paper I have attempted implications of the successful merger from July 05, 2000 till date in Glaxo Wellcome with Smith Kline Beecham. GlaxoSmithKline plc is a leading research-based pharmaceutical company of the world, has had a presence in India since 1924, and is a leading pharmaceutical company in the country today, employing more than 20,000 people. GSK India is organized into three business seg ment: Pharmaceuticals the predominant business, Agrivet Farm care and QualigensRead MoreGsk Annual Report 2010135604 Words   |  543 PagesSynï ¬â€šorix at a reduced price to developing countries over the next decade through the AMC ï ¬ nancing mechanism. 5-year commitment To treat school age children in Africa at risk of intestinal worms. Leader GSK ranked ï ¬ rst in both Access to Medicine Indexes in 2008 and 2010. 2050 Target date for value chain, from raw materials to product disposal, to be carbon neutral. Shareholder information P192–P212 Core Pharmaceutical RD To ï ¬ nd out more visit us at www.gsk.com/corporatereporting GSK Annual ReportRead MoreCsr Communication in the Pharma Industry35538 Words   |  143 Pagesscientific paradigm. Approached from a critic-interpretative perspective, the first part of this study proposes a theoretical framework, grounded on theories from experts in the fields of corporate communication and Corporate Social Responsibility (CSR). After a theoretical analysis of the pharmaceutical industry, the research includes the development of an analytical framework, which serves as a basis for the examination of the selected websites. This is followed by an analysis based on the CSR sectionRead MoreNursing Essay41677 Words   |  167 Pagesmultitude of complex health concerns that face the United States and the world. Equally important is the timely implementation of those solutions in a way that improves health. The United States is at an important crossroads as health care reforms are being carried out and the system begins to change. The possibility of strengthening the la rgest component of the health care workforce—nurses—to become partners and leaders in improving the delivery of care and the health care system as a whole inspiredRead More3m Pharma Health Care Market Analysis19832 Words   |  80 Pagesorganizations (CMOs) make them increasingly indispensable to companies. Greater emphasis has been put on European CMOs to leverage low-cost contract manufacturing markets, such as those existing in India and China, to enhance cost efficiency (Contract Pharma, 2008-2023). More and more pharmaceutical companies are going for outsourcing for their key products. The decision to outsource is often referred to as a make or bye decision, with make meaning to perform a function in the house and buy meaning to source